SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

RP-A601

RCKT·ROCKET PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
Likely several years away, if successful. The program is still in Phase 1 with no Phase 2/3 design announced.
Why 4/10
RP-A601 is in Phase 1 with no scheduled pivotal readout or PDUFA date in the next ~12 months. The next catalyst is a regulatory update on Phase 2 path, which is not a hard binary event. The drug is one of three prioritized cardiovascular gene therapy programs at Rocket, alongside RP-A501 (Danon disease, pivotal Phase 2 data expected early 2027) and RP-A701 (BAG3-DCM).
Actionable Insight NEUTRAL

RP-A601 is an early-stage gene therapy program with encouraging but very preliminary Phase 1 data. The next meaningful catalyst is likely a regulatory update on Phase 2 trial design, which Rocket has not yet scheduled. Investors should watch for updates in Rocket's quarterly earnings calls and whether the company provides a timeline for advancing RP-A601 into a Phase 2/3 study. The stock's primary near-term value driver is RP-A501 for Danon disease, with pivotal Phase 2 data expected in early 2027.

Price Chart

Loading chart...

Executive Summary

RP-A601 is an AAV9-based gene therapy from Rocket Pharmaceuticals (RCKT) for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM), a rare genetic heart disease affecting roughly 50,000 people in the US and EU. It is in Phase 1 clinical development with preliminary data from May 2025 showing early safety and signals of efficacy. The FDA has granted it Fast Track, Orphan Drug, and RMAT designations. However, RP-A601 is still early-stage and is one of three prioritized cardiovascular gene therapy programs at Rocket. The stock trades near $2.31, down sharply from its 52-week high of $5.45, reflecting the clinical hold and death that occurred in the RP-A501 Danon disease program in May 2025 (a separate program), which severely impacted investor sentiment across the company. RP-A601 faces competition from Tenaya Therapeutics' TN-401, a similar PKP2 gene therapy in Phase 1b/2.

How It Works

RP-A601 is an experimental gene therapy that uses a harmless virus (AAV9) to deliver a working copy of the PKP2 gene directly into heart muscle cells. PKP2 mutations cause a genetic heart condition where the heart muscle is replaced by fatty or fibrous tissue, leading to dangerous heart rhythms and sudden cardiac death. By restoring the missing protein, the therapy aims to stabilize heart cells and prevent life-threatening arrhythmias.

Trial Status

RP-A601 is in an ongoing Phase 1 dose-escalation clinical trial for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM). Preliminary data were presented as a late-breaking oral presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in May 2025. The data showed early signs of safety and efficacy, including reductions in ventricular arrhythmia burden and improvements in quality-of-life measures. The company has received FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT) designations for RP-A601, as well as Orphan Medicinal Product designation from the European Commission. Rocket is engaging with the FDA on the path forward, but no Phase 2/3 trial design has been announced as of the Q3 2026 earnings report (November 12, 2026).

The Two-Sided Case

▲ Bull Case1
RP-A601 targets a validated genetic cause of a life-threatening heart disease with no approved disease-modifying therapies, representing a large unmet need. Preliminary Phase 1 data showed reductions in ventricular arrhythmia burden and improved quality-of-life measures. FDA has granted RMAT, Fast Track, and Orphan Drug designations, which could accelerate development and regulatory review. Rocket has a fully integrated gene therapy platform and manufacturing capabilities, with one product (KRESLADI) already FDA-approved.
▼ Bear Case1
RP-A601 is still in early Phase 1 with no Phase 2/3 trial design announced, making it years away from any potential approval. The company's lead gene therapy program RP-A501 suffered a clinical hold and patient death in May 2025, raising safety concerns about the AAV9 platform more broadly. Rocket's cash runway extends only into Q2 2027 (roughly $188.9M as of year-end 2025), and the stock has fallen over 50% from its 52-week high. Tenaya Therapeutics' TN-401 is a direct competitor targeting the same PKP2 mutation and is already in Phase 1b/2. Insider selling has been ongoing, with the General Counsel and CEO both selling shares in recent months.

Upcoming Catalysts

  • Regulatory update on Phase 2 path for RP-A601 (timing not yet announced)
  • Rocket Q4 2026 earnings and pipeline update (expected early 2027)
  • Pivotal Phase 2 data for RP-A501 in Danon disease (expected early 2027), which could derisk the broader AAV9 platform

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ROCKET PHARMACEUTICALS, INC. CLUSTER RCKT ·Originating report

Sources · 13

Hover a chip for the title
1 businesswire.com2 businesswire.com3 businesswire.com4 investing.com5 benzinga.com6 nasdaq.com7 businesswire.com8 nasdaq.com9 nasdaq.com10 nasdaq.com11 streetinsider.com12 seekingalpha.com13 rutlandherald.com